Today is World Psoriasis Day . The latest news shows that two new specifications of innovative biological agent Keshanting (Tscuchiyouzumab) have been approved by National Medical Products Administration - 300mg of Worry-free Suixing Pen and 75mg of Pre-filled Injection Psoriasis Indications for Children have been extended to patients aged 6 years and older who meet the indications of systemic treatment or phototherapy, and are no longer subject to weight limitation. With the approval of the new specification, Keshanting has become the only fully human interleukin inhibitor in my country with three specifications (300mg, 150mg, 75mg), providing more comprehensive choices for more Chinese patients. Zhang Ying, President of Novartis Innovation Drugs, said: "Building an innovative ecosystem centered on patient needs and maximizing patient benefits is the goal of Novartis . Every child, adolescent and adult patients needs care. Keshanting's children's indications extension and the approval of new specifications will benefit a wider group. We will continue to pay attention to patient needs, bring innovative treatment options, and help more patients get better disease management and experience."
two injections into one injection, improving the treatment experience in all aspects
psoriasis is an immune-related chronic, recurrent, inflammatory, and systemic disease. At present, there are more than 6.5 million psoriasis patients in my country. Because the disease cannot be cured, patients need to follow standardized and reasonable treatment plans for a long time to obtain good disease control and achieve complete clearance of the skin lesions. In clinical treatment, persistence in treatment is a great challenge for patients. In June 2020, Keshanting 150mg self-sensing pen was approved in China. The patients can inject themselves at home after being guided by a doctor. They will not see the needle during use, which reduces injection anxiety and greatly improves the patient's compliance and treatment experience. The conventional treatment dose for most patients with psoriasis is 300 mg each time, that is, a single 2 injections of 150 mg subcutaneously. The approval of
300mg for worry-free pen enables psoriasis patients to achieve satisfactory symptom control with fewer injections. is simplified from 2 injections per single shot 150mg to 300mg per single shot. 's more simplified treatment method brings patients a more relaxed treatment experience. In addition, studies have shown that the efficacy and safety of 300mg of Worry-free Suixin Pen are comparable to 2 injections of 150mg, and the incidence of adverse reactions at the injection site is less than 0.1%.
Tscuchiyuzumab chief scientist in China's Phase III and Phase IV clinical research and director of the Dermatology Department of Peking University People's Hospital emphasized: "As clinicians, we hope to meet the needs of every patient as much as possible. Patients with psoriasis of different ages and weights use different doses of Keshanting. A simpler operation is conducive to patients with convenient medication. Keshanting is currently the only clinically approved three different specifications of biological agents: 300mg, 150mg and 75mg. Under the advice of the doctor, users can choose different specifications of products according to their own needs. Only one injection is required for a single treatment, which will help promote patients to adhere to standardized medication and achieve a better quality of life. "
is no longer limited by weight, and it will fully benefit patients aged 6 and above
In recent years, the number of reported psoriasis in children in my country has been on an upward trend, with about one-third of cases starting in childhood, and is common in adolescence. The disease not only brings a heavy physical and mental burden to the children and their families, but the persistent inflammatory response may also lead to a series of complications such as arthritis and cardiovascular disease over time. While children are unable to heal skin itching, they are also prone to prejudice and discrimination, and are prone to inferiority and avoidance, which brings a heavy mental burden to children who are in this sensitive and special stage of life.
"The impact of psoriasis on children is far more than the skin, it may even cause damage to the entire life course of the children. The quality of life of these children is often worse than their peers and further affects their emotional health and school performance." Professor Ma Lin, director of the Department of Dermatology at Beijing Children's Hospital Affiliated to Capital Medical University, said that early active and effective treatment is very critical to reducing the accumulated damage of the disease. Since Keshanting was approved for indications for psoriasis in children and adolescents in 2021, children with weighing less than 50kg cannot be used due to their weight. Many parents are looking forward to smaller-sized products to be approved for market as soon as possible.The approval of the new specification of 75mg brings hope to more children's families and can effectively improve the overall quality of life of children with moderate to severe psoriasis.
The treatment of childhood psoriasis must take into account both efficacy and long-term safety. Studies have shown that Keshanting treats psoriasis with 12 weeks of adverse events, and is similar to placebo and continues to receive treatment for 52 weeks. No new/unexpected safety issues were found in the low-dose treatment group or the high-dose treatment group.
is currently the world's first and only fully human interleukin inhibitor, Keshanting can specifically neutralize IL-17A from multiple sources, inhibit its proinflammatory effects, and bring a breakthrough treatment plan for patients with moderate to severe plaque psoriasis. In China, Keshanting has successively approved the treatment of "adults of moderate to severe plaque psoriasis that meet the indications of systemic therapy or phototherapy and children aged 6 years and above with a weight of ≥50kg" and "adult patients with ankylosing spondylitis with poor conventional treatment" and was officially included in the National Medical Insurance Catalog in 2020. The approval of the new specification and the expansion of pediatric indications will further benefit more Chinese patients.
Author: Tang Wenjia
Editor: Tang Wenjia
Source: Interviewed
